BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 15020611)

  • 1. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.
    Devine SM; Flomenberg N; Vesole DH; Liesveld J; Weisdorf D; Badel K; Calandra G; DiPersio JF
    J Clin Oncol; 2004 Mar; 22(6):1095-102. PubMed ID: 15020611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma.
    Grignani G; Perissinotto E; Cavalloni G; Carnevale Schianca F; Aglietta M
    J Clin Oncol; 2005 Jun; 23(16):3871-2; author reply 3872-3. PubMed ID: 15923599
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
    Stewart DA; Smith C; MacFarland R; Calandra G
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
    Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients.
    Gazitt Y; Freytes CO; Akay C; Badel K; Calandra G
    Stem Cells Dev; 2007 Aug; 16(4):657-66. PubMed ID: 17784839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.
    Basak GW; Knopinska-Posluszny W; Matuszak M; Kisiel E; Hawrylecka D; Szmigielska-Kaplon A; Urbaniak-Kujda D; Dybko J; Zielinska P; Dabrowska-Iwanicka A; Werkun J; Rzepecki P; Wroblewska W; Wiktor-Jedrzejczak W
    Ann Hematol; 2011 May; 90(5):557-68. PubMed ID: 20938660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.
    Liles WC; Broxmeyer HE; Rodger E; Wood B; Hübel K; Cooper S; Hangoc G; Bridger GJ; Henson GW; Calandra G; Dale DC
    Blood; 2003 Oct; 102(8):2728-30. PubMed ID: 12855591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.
    Calandra G; McCarty J; McGuirk J; Tricot G; Crocker SA; Badel K; Grove B; Dye A; Bridger G
    Bone Marrow Transplant; 2008 Feb; 41(4):331-8. PubMed ID: 17994119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).
    De Clercq E
    Biochem Pharmacol; 2009 Jun; 77(11):1655-64. PubMed ID: 19161986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
    Dugan MJ; Maziarz RT; Bensinger WI; Nademanee A; Liesveld J; Badel K; Dehner C; Gibney C; Bridger G; Calandra G
    Bone Marrow Transplant; 2010 Jan; 45(1):39-47. PubMed ID: 19483760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plerixafor: a peripheral blood stem cell mobilizer.
    Kessans MR; Gatesman ML; Kockler DR
    Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
    Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
    Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
    Brave M; Farrell A; Ching Lin S; Ocheltree T; Pope Miksinski S; Lee SL; Saber H; Fourie J; Tornoe C; Booth B; Yuan W; He K; Justice R; Pazdur R
    Oncology; 2010; 78(3-4):282-8. PubMed ID: 20530974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent.
    Cashen AF; Nervi B; DiPersio J
    Future Oncol; 2007 Feb; 3(1):19-27. PubMed ID: 17280498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
    Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.